Last edition
News about "AstraZeneca"
Syneron Bio Signs Strategic Partnership with AstraZeneca
Under this collaboration, AstraZeneca will gain access to Syneron Bio's innovative Synova™ platform, an intelligent and high-throughput macrocyclic peptide drug research and development platform, designed to support the advancements of research programmes exploring possible future treatments of chronic diseases.
AstraZeneca | 24/03/2025 | By Aishwarya | 270
AstraZeneca Signs License Deal with Alteogen for ALT-B4
Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets.
AstraZeneca | 18/03/2025 | By Aishwarya
CHMP Recommends T-DXd EU Approval in HER2-Low/Ultralow Breast Cancer
ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
AstraZeneca | 04/03/2025 | By Aishwarya
AstraZeneca To Invest CAD 820 Mn in Canada to Boost Clinical Delivery Sector
New investment in Canada will contribute to AstraZeneca’s global ambition to achieve USD80 billion in Total Revenue and to bring 20 new medicines to patients around the world by 2030 of which eight new medicines have been delivered to date.
AstraZeneca | 27/01/2025 | By Aishwarya
AstraZeneca Gains CDSCO Nod for Import of Eculizumab in India
Eculizumab is a monoclonal antibody used to treat Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement-mediated thrombotic microangiopathy.
AstraZeneca | 18/01/2025 | By Aishwarya
Lunit, AstraZeneca to Develop AI-Powered Digital Pathology Tools for NSCLC
Lunit’s collaboration with AstraZeneca aims to transform the speed and accuracy of detecting actionable mutations in NSCLC.
AstraZeneca | 19/11/2024 | By Aishwarya
AstraZeneca Announces Investment of USD 3.5 Billion in R&D in US
AstraZeneca’s expanding footprint in the US includes, a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts, a next generation manufacturing facility for biologics in Maryland, cell therapy manufacturing capacity on the West and East Coasts and a specialty manufacturing in Texas.
AstraZeneca | 14/11/2024 | By Aishwarya
EMA Accepts Approval for AstraZeneca MAA for Sipavibart
AstraZeneca has announced that its Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients.
AstraZeneca | 02/07/2024 | By Aishwarya | 210
AstraZeneca Completes Acquisition of Fusion
AstraZeneca has completed the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
AstraZeneca | 06/06/2024 | By Aishwarya | 141
Nona Biosciences Signs License Deal with AstraZeneca for Monoclonal Antibody Development
Nona Biosciences has signed a license deal with AstraZeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.
AstraZeneca | 27/05/2024 | By Aishwarya | 183
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy